Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + cisplatin + nab-paclitaxel as first-line therapy for advanced biliary tract cancer (single-arm phase II)
ChiCTR2000036850Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, cisplatin and paclitaxel in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA) and 1 more, sponsored by West China Hospital of Sichuan University. Primary endpoints: Median progression-free survival and Median overall survival. Started Aug 2020; status: recruiting.
02
Drugs
gemcitabinecisplatinpaclitaxel
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2000036850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036850.